In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well tolerated in both healthy adult subjects and patients with ESKD.
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”
Warren Buffett
Recent CVKD News
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:05:43 PM
- Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes • GlobeNewswire Inc. • 03/12/2026 12:00:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 01:35:37 PM
- Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement • GlobeNewswire Inc. • 02/24/2026 01:30:00 PM
- Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor • GlobeNewswire Inc. • 01/12/2026 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/02/2026 09:05:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/02/2026 05:15:35 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/29/2025 09:25:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 09:58:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/23/2025 09:56:48 PM
- Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 • GlobeNewswire Inc. • 12/17/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2025 01:24:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/16/2025 01:21:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/16/2025 01:18:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2025 01:17:00 PM
- Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) • GlobeNewswire Inc. • 12/11/2025 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 02:05:24 PM
- Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors • GlobeNewswire Inc. • 12/01/2025 02:00:00 PM
- Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award • GlobeNewswire Inc. • 11/19/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2025 09:23:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/18/2025 09:20:04 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
